Merit Financial Group LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Merit Financial Group LLC lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 868 shares of the biopharmaceutical company’s stock after purchasing an additional 71 shares during the period. Merit Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $618,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals during the third quarter worth about $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $49,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.1 %

REGN opened at $680.03 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $733.06 and its 200-day moving average price is $943.95. The company has a market cap of $74.73 billion, a P/E ratio of 16.83, a P/E/G ratio of 1.61 and a beta of 0.10.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on REGN shares. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research note on Thursday, October 24th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, Evercore ISI lowered their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.